UY31907A - Compuesto heterociclico y su uso - Google Patents

Compuesto heterociclico y su uso

Info

Publication number
UY31907A
UY31907A UY0001031907A UY31907A UY31907A UY 31907 A UY31907 A UY 31907A UY 0001031907 A UY0001031907 A UY 0001031907A UY 31907 A UY31907 A UY 31907A UY 31907 A UY31907 A UY 31907A
Authority
UY
Uruguay
Prior art keywords
heterociclical
compound
hypertension
prodrugs
formulas
Prior art date
Application number
UY0001031907A
Other languages
English (en)
Inventor
Takanobu Kuroita
Imaeda Yasuhiro
Iwanaga Kouichi
Taya Naohiro
Tokuhara Hidekazu
Fukase Yoshiyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31907(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY31907A publication Critical patent/UY31907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos representados por las fórmulas en donde cada símbolo es como se definió en la memoria descriptiva y uno de sus profármacos tiene una actividad inhibidora de renina superior y son de utilidad como agentes para la prevención o el tratamiento de hipertensión, diversos daños orgánicos atribuibles a la hipertensión, y similares.
UY0001031907A 2008-06-19 2009-06-17 Compuesto heterociclico y su uso UY31907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008161049 2008-06-19
JP2009004882 2009-01-13

Publications (1)

Publication Number Publication Date
UY31907A true UY31907A (es) 2010-01-29

Family

ID=41282529

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031907A UY31907A (es) 2008-06-19 2009-06-17 Compuesto heterociclico y su uso

Country Status (38)

Country Link
US (5) US8466282B2 (es)
EP (1) EP2297114B1 (es)
JP (3) JP4800445B2 (es)
KR (2) KR101207830B1 (es)
CN (2) CN102123990B (es)
AR (1) AR072166A1 (es)
AU (1) AU2009261153B2 (es)
BR (1) BRPI0914802B8 (es)
CA (1) CA2728476C (es)
CL (1) CL2010001361A1 (es)
CO (1) CO6300862A2 (es)
CR (2) CR20110001A (es)
CY (1) CY1120995T1 (es)
DK (1) DK2297114T3 (es)
DO (2) DOP2010000381A (es)
EA (2) EA019755B1 (es)
EC (1) ECSP11010770A (es)
ES (1) ES2676289T3 (es)
GE (2) GEP20135957B (es)
HR (1) HRP20181370T1 (es)
HU (1) HUE039416T2 (es)
IL (1) IL209282A (es)
JO (1) JO3465B1 (es)
LT (1) LT2297114T (es)
MA (1) MA32483B1 (es)
MX (2) MX2010013602A (es)
MY (1) MY160771A (es)
NZ (2) NZ589825A (es)
PE (2) PE20110067A1 (es)
PL (1) PL2297114T3 (es)
PT (1) PT2297114T (es)
RS (1) RS57591B1 (es)
SG (1) SG188117A1 (es)
SI (1) SI2297114T1 (es)
TW (2) TWI472523B (es)
UY (1) UY31907A (es)
WO (1) WO2009154300A2 (es)
ZA (1) ZA201009073B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
TWI434690B (zh) 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
CA2728476C (en) * 2008-06-19 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic carboxamide compounds and their use in the prophylaxis or treatment of hypertension
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
TWI511967B (zh) * 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
CN103189370B (zh) * 2010-11-09 2015-07-08 霍夫曼-拉罗奇有限公司 作为gaba受体用配体的三唑衍生物
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2013123153A1 (en) * 2012-02-14 2013-08-22 Dow Global Technologies Llc Nonionic surfactant compositions
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CN104411703A (zh) * 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
JP6446034B2 (ja) * 2014-04-10 2018-12-26 武田薬品工業株式会社 複素環化合物の製造法
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2168510C2 (ru) 1991-07-31 2001-06-10 Такеда Кемикал Индастриз, Лтд. Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
DK0832066T3 (da) 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
TR199700334T1 (tr) 1995-09-01 1997-08-21 Lilly Co Eli Indolil nöropeptid y reseptör antagonistleri.
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
CZ2004747A3 (cs) 2001-12-21 2004-11-10 Novo Nordisk A/S Deriváty amidů jako GK aktivátory
CA2478068C (en) 2002-03-08 2011-02-08 Merck & Co., Inc. Dihydropyrazole compounds useful for treating or preventing cancer
US7235580B2 (en) 2002-10-18 2007-06-26 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
US7465746B2 (en) 2003-08-15 2008-12-16 Merck & Co., Inc. Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP
JP2007502773A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
US7989634B2 (en) 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
MX2007001540A (es) 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
RU2440993C2 (ru) 2004-10-07 2012-01-27 Вайти Фармасьютикл, Инк. Диаминоалкановые ингибиторы аспарагиновой протеазы
CN101048383A (zh) * 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1861097A4 (en) 2005-03-16 2010-01-13 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
GB0511063D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007026664A1 (ja) 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
ES2430139T3 (es) * 2005-12-30 2013-11-19 Novartis Ag Compuestos de piperidina 3,5-sustituido como inhibidores de renina
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
CA2638787A1 (en) 2006-02-16 2007-08-23 Takeda Pharmaceutical Company Limited Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
US7790884B2 (en) * 2006-03-24 2010-09-07 Astellas Pharma Inc. Acylaminopiperidine compound
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
JP2009544602A (ja) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド サイクリン依存性キナーゼ阻害剤の医学的使用
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US20100056497A1 (en) * 2007-01-31 2010-03-04 Dainippon Sumitomo Pharma Co., Ltd Amide derivative
JP4837701B2 (ja) 2007-04-20 2011-12-14 田辺三菱製薬株式会社 医薬組成物
US20090156612A1 (en) 2007-04-27 2009-06-18 Takanobu Kuroita Substituted imidazole compound and use thereof
JP2010163361A (ja) * 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
JP2010189275A (ja) 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
TWI452044B (zh) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
WO2009001915A1 (ja) 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
JP2010208947A (ja) * 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd キノロン誘導体
JP2010229034A (ja) * 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
JP5441705B2 (ja) * 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
JP2011037712A (ja) 2007-12-08 2011-02-24 Dainippon Sumitomo Pharma Co Ltd ４−アリールフェニル誘導体
TWI434690B (zh) 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
AR070454A1 (es) 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) * 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾチアゾール誘導体
CA2728476C (en) * 2008-06-19 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic carboxamide compounds and their use in the prophylaxis or treatment of hypertension
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬

Also Published As

Publication number Publication date
KR101207830B1 (ko) 2012-12-04
US20100137587A1 (en) 2010-06-03
SI2297114T1 (sl) 2018-10-30
BRPI0914802A2 (pt) 2015-08-11
AU2009261153A1 (en) 2009-12-23
NZ600238A (en) 2014-04-30
MX2010013602A (es) 2011-03-15
MX338557B (es) 2016-04-21
ES2676289T3 (es) 2018-07-18
IL209282A0 (en) 2011-01-31
CA2728476C (en) 2017-03-21
ZA201009073B (en) 2012-03-28
CY1120995T1 (el) 2019-12-11
US20110178057A1 (en) 2011-07-21
JP4800445B2 (ja) 2011-10-26
EA201301040A1 (ru) 2014-01-30
WO2009154300A2 (en) 2009-12-23
KR20120084778A (ko) 2012-07-30
NZ589825A (en) 2012-11-30
BRPI0914802B1 (pt) 2020-10-27
CN103373985B (zh) 2015-10-28
DK2297114T3 (en) 2018-07-09
US20120264733A1 (en) 2012-10-18
US20160046601A1 (en) 2016-02-18
LT2297114T (lt) 2018-08-10
CN103373985A (zh) 2013-10-30
SG188117A1 (en) 2013-03-28
CR20130360A (es) 2013-09-03
US20150191486A1 (en) 2015-07-09
WO2009154300A3 (en) 2010-06-03
PE20140858A1 (es) 2014-08-04
ECSP11010770A (es) 2011-02-28
MY160771A (en) 2017-03-15
BRPI0914802B8 (pt) 2021-05-25
KR20110019428A (ko) 2011-02-25
CO6300862A2 (es) 2011-07-21
CL2010001361A1 (es) 2011-07-29
JP2014094950A (ja) 2014-05-22
AU2009261153B2 (en) 2014-05-22
JP2011157391A (ja) 2011-08-18
CR20110001A (es) 2013-03-15
PT2297114T (pt) 2018-07-26
EP2297114B1 (en) 2018-06-06
IL209282A (en) 2015-07-30
US8466282B2 (en) 2013-06-18
TW201002685A (en) 2010-01-16
US9045436B2 (en) 2015-06-02
MA32483B1 (fr) 2011-07-03
US9221836B2 (en) 2015-12-29
DOP2013000123A (es) 2013-11-15
DOP2010000381A (es) 2010-12-31
CN102123990A (zh) 2011-07-13
EA201170051A1 (ru) 2011-08-30
RS57591B1 (sr) 2018-11-30
JP5918746B2 (ja) 2016-05-18
PE20110067A1 (es) 2011-02-18
TWI472523B (zh) 2015-02-11
CN102123990B (zh) 2014-07-09
TW201240987A (en) 2012-10-16
EP2297114A2 (en) 2011-03-23
KR101578264B1 (ko) 2015-12-16
JP2011524853A (ja) 2011-09-08
JO3465B1 (ar) 2020-07-05
HRP20181370T1 (hr) 2018-10-19
TWI378096B (en) 2012-12-01
PL2297114T3 (pl) 2018-10-31
EA019755B1 (ru) 2014-06-30
JP5592831B2 (ja) 2014-09-17
US8664380B2 (en) 2014-03-04
GEP20135957B (en) 2013-11-11
AR072166A1 (es) 2010-08-11
GEP20166443B (en) 2016-03-10
HUE039416T2 (hu) 2018-12-28
CA2728476A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
UY31907A (es) Compuesto heterociclico y su uso
NI201001031A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
CR20110135A (es) INHIBIDORES DE cMET
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
EA200801739A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA201100424A1 (ru) Новые ингибиторы
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
AR066268A1 (es) Compuesto de imidazol sustituido y su uso
UY30628A1 (es) Inhibidores de metaloproteasas de matriz
UY31479A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
UY31849A (es) Nuevos compuestos como inhibidores de pde4
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
ECSP11010849A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
GT200600208A (es) Compuestos organicos
ECSP088781A (es) Derivados de benzimidazol
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa
NO20091081L (no) Oganiske forbindelser
ECSP066818A (es) Proceso para la preparacion de inhibidores de triptasa
CR20110405A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181105